Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas - Tabular View

Tracking Information
First Received Date ^ICMJE	August 24, 2001
Last Updated Date	June 23, 2005
Start Date ^ICMJE	May 2001
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00023166 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
Official Title ^ICMJE	Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas
Brief Summary	Studies of PEG-paclitaxel have been terminated
Detailed Description
Study Phase	Phase I
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Condition ^ICMJE	Neoplasm Lymphomas Neoplasm Metastasis
Intervention ^ICMJE	Drug: PEG-paclitaxel
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Terminated
Enrollment ^ICMJE
Completion Date	May 2002
Primary Completion Date
Eligibility Criteria ^ICMJE	None - Study has been terminated.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE

Administrative Information
NCT ID ^ICMJE	NCT00023166
Responsible Party
Study ID Numbers ^ICMJE	PTX-5001
Study Sponsor ^ICMJE	Enzon Pharmaceuticals, Inc.
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Enzon Pharmaceuticals, Inc.
Verification Date	March 2004
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP